{
    "name": "goserelin",
    "comment": "Rx",
    "other_names": [
        "Zoladex",
        "Zoladex LA"
    ],
    "classes": [
        "Antineoplastics",
        "GNRH Agonists"
    ],
    "source": "https://reference.medscape.com/drug/zoladex-la-goserelin-342129",
    "pregnancy": {
        "common": [
            "Contraindicated during pregnancy unless being used for palliative treatment of advanced breast cancer",
            "Based on mechanism of action in humans and findings of increased pregnancy loss in animal studies, goserelin can cause fetal harm when administered to pregnant females"
        ],
        "specific": []
    },
    "lactation": {
        "common": []
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to LHRH, LHRH-agonists, any component of product",
                "Pregnancy (for endometriosis), lactation, undiagnosed abnormal vaginal bleeding"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity, antibody formation, and acute anaphylactic reactions reported with GnRH agonist analogues ",
                "Hypercalcemia reported in some patients with prostate or breast cancer with bone metastases after starting treatment ",
                "Pharmacologic action on the uterus and cervix may cause an increase in cervical resistance; care should be taken when dilating the cervix for endometrial ablation "
            ],
            "specific": [
                {
                    "type": "Women of childbearing potential and pregnancy ",
                    "description": [
                        "Before initiating, pregnancy must be excluded in females for benign gynecological conditions ",
                        "Effective nonhormonal contraception must be used by all premenopausal females during therapy and for 12 weeks following discontinuation of therapy ",
                        "When used every 28 days, goserelin usually inhibits ovulation and stops menstruation; however, pregnancy prevention is not ensured ",
                        "Effects on reproductive function are expected to occur with chronic administration as a result of the drugâ€™s anti-gonadotrophic properties ",
                        "Based on mechanism of action in humans and findings of increased pregnancy loss in animal studies, can cause fetal harm when administered to a pregnant females ",
                        "If used during pregnancy for palliative treatment of breast cancer, inform patient of potential hazard to fetus "
                    ]
                },
                {
                    "type": "Tumor flare ",
                    "description": [
                        "Initially, like other GnRH agonists, causes transient increases in serum levels of testosterone in men with prostate cancer, and estrogen in females with breast cancer ",
                        "Transient worsening of symptoms, or occurrence of additional signs and symptoms of prostate or breast cancer, may occasionally develop during the first few weeks of treatment ",
                        "A few patients may experience a temporary increase in bone pain, which can be managed symptomatically ",
                        "As with other GnRH agonists, isolated cases of ureteral obstruction and spinal cord compression observed in patients with prostate cancer ",
                        "If spinal cord compression or renal impairment secondary to ureteral obstruction develops, initiate standard treatment for these complications ",
                        "For extreme cases in prostate cancer patients, consider an immediate orchiectomy "
                    ]
                },
                {
                    "type": "Hyperglycemia and diabetes ",
                    "description": [
                        "Hyperglycemia and increased risk of developing diabetes reported in men receiving GnRH agonists ",
                        "Hyperglycemia may represent development of diabetes mellitus or worsening of glycemic control in patients with diabetes ",
                        "Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically in patients receiving a GnRH agonist and manage with current practice for treatment of hyperglycemia or diabetes "
                    ]
                },
                {
                    "type": "Cardiovascular diseases ",
                    "description": [
                        "Increased risk of developing myocardial infarction, sudden cardiac death, and stroke reported in association with use of GnRH agonists in men ",
                        "Risk appears low based on reported odds ratios, and should be evaluated carefully along with cardiovascular (CV) risk factors when determining a treatment for patients with prostate cancer ",
                        "Patients receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of CV disease and be managed according to current clinical practice "
                    ]
                },
                {
                    "type": "QT/QTc interval prolongation ",
                    "description": [
                        "Androgen deprivation therapy may prolong the QT/QTc interval ",
                        "Consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and coadministration of drugs known to prolong the QT interval ",
                        "Correct electrolyte abnormalities before initiating ",
                        "Consider periodic monitoring of electrolytes and performing ECG "
                    ]
                },
                {
                    "type": "Injection site injury ",
                    "description": [
                        "Injection site injury and vascular injury including pain, hematoma, hemorrhage and hemorrhagic shock, requiring blood transfusions and surgical intervention, reported ",
                        "Extra care should be taken when administering to patients with a low BMI and/or to patients receiving full dose anticoagulation "
                    ]
                },
                {
                    "type": "Depression ",
                    "description": [
                        "Depression may occur or worsen in women during treatment with GnRH agonists including goserelin 3.6 mg",
                        "Carefully observe women for depression, especially those with history of depression and consider whether risks of continuing goserelin 3.6 mg outweigh benefits",
                        "Refer females with new or worsening depression to a mental health professional, as appropriate "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "amiodarone",
            "description": {
                "common": "goserelin increases toxicity of amiodarone by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "anagrelide",
            "description": {
                "common": "goserelin increases toxicity of anagrelide by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "arsenic trioxide",
            "description": {
                "common": "goserelin increases toxicity of arsenic trioxide by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "artemether",
            "description": {
                "common": "goserelin increases toxicity of artemether by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "goserelin increases toxicity of artemether/lumefantrine by QTc interval. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "citalopram",
            "description": {
                "common": "goserelin increases toxicity of citalopram by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "disopyramide",
            "description": {
                "common": "goserelin increases toxicity of disopyramide by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dofetilide",
            "description": {
                "common": "goserelin increases toxicity of dofetilide by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dronedarone",
            "description": {
                "common": "goserelin increases toxicity of dronedarone by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eliglustat",
            "description": {
                "common": "goserelin increases toxicity of eliglustat by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "escitalopram",
            "description": {
                "common": "goserelin increases toxicity of escitalopram by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "goserelin increases toxicity of fluoxetine by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ibutilide",
            "description": {
                "common": "goserelin increases toxicity of ibutilide by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "iloperidone",
            "description": {
                "common": "goserelin increases toxicity of iloperidone by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lopinavir",
            "description": {
                "common": "goserelin increases toxicity of lopinavir by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lumefantrine",
            "description": {
                "common": "goserelin increases toxicity of lumefantrine by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mifepristone",
            "description": {
                "common": "goserelin increases toxicity of mifepristone by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nilotinib",
            "description": {
                "common": "goserelin increases toxicity of nilotinib by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "paliperidone",
            "description": {
                "common": "goserelin increases toxicity of paliperidone by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pimozide",
            "description": {
                "common": "goserelin increases toxicity of pimozide by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "procainamide",
            "description": {
                "common": "goserelin increases toxicity of procainamide by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "quetiapine",
            "description": {
                "common": "goserelin increases toxicity of quetiapine by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "quinidine",
            "description": {
                "common": "goserelin increases toxicity of quinidine by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sotalol",
            "description": {
                "common": "goserelin increases toxicity of sotalol by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tetrabenazine",
            "description": {
                "common": "goserelin increases toxicity of tetrabenazine by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "thioridazine",
            "description": {
                "common": "goserelin increases toxicity of thioridazine by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "toremifene",
            "description": {
                "common": "goserelin increases toxicity of toremifene by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "vandetanib",
            "description": {
                "common": "goserelin increases toxicity of vandetanib by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "vemurafenib",
            "description": {
                "common": "goserelin increases toxicity of vemurafenib by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "goserelin increases toxicity of ziprasidone by QTc interval. Contraindicated. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride and goserelin both increase  QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "buprenorphine and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "buprenorphine buccal and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine subdermal implant",
            "description": {
                "common": "buprenorphine subdermal implant and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine transdermal",
            "description": {
                "common": "buprenorphine transdermal and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "buprenorphine, long-acting injection and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desflurane",
            "description": {
                "common": "desflurane and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "entrectinib",
            "description": {
                "common": "goserelin and entrectinib both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole and goserelin both increase  QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glasdegib",
            "description": {
                "common": "goserelin and glasdegib both increase  QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "inotuzumab",
            "description": {
                "common": "inotuzumab and goserelin both increase  QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isoflurane",
            "description": {
                "common": "isoflurane and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lefamulin",
            "description": {
                "common": "lefamulin and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lithium",
            "description": {
                "common": "lithium and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olanzapine",
            "description": {
                "common": "olanzapine and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "panobinostat",
            "description": {
                "common": "goserelin and panobinostat both increase  QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pitolisant",
            "description": {
                "common": "goserelin and pitolisant both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sevoflurane",
            "description": {
                "common": "sevoflurane and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and goserelin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albuterol",
            "description": {
                "common": "albuterol and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "goserelin and alfuzosin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apomorphine",
            "description": {
                "common": "goserelin increases toxicity of apomorphine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arformoterol",
            "description": {
                "common": "goserelin increases toxicity of arformoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "aripiprazole and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atomoxetine",
            "description": {
                "common": "atomoxetine and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azithromycin",
            "description": {
                "common": "goserelin increases toxicity of azithromycin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bedaquiline",
            "description": {
                "common": "goserelin increases toxicity of bedaquiline by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosutinib",
            "description": {
                "common": "bosutinib and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "capecitabine",
            "description": {
                "common": "capecitabine and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceritinib",
            "description": {
                "common": "goserelin increases toxicity of ceritinib by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloroquine",
            "description": {
                "common": "goserelin increases toxicity of chloroquine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "goserelin increases toxicity of chlorpromazine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "goserelin decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "goserelin increases toxicity of ciprofloxacin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "goserelin increases toxicity of clarithromycin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "goserelin increases toxicity of clozapine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crizotinib",
            "description": {
                "common": "goserelin increases toxicity of crizotinib by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dasatinib",
            "description": {
                "common": "dasatinib and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "degarelix",
            "description": {
                "common": "goserelin increases toxicity of degarelix by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "goserelin decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "desipramine and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deutetrabenazine",
            "description": {
                "common": "deutetrabenazine and goserelin both increase  QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dolasetron",
            "description": {
                "common": "goserelin increases toxicity of dolasetron by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "donepezil",
            "description": {
                "common": "donepezil and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "doxepin and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "droperidol",
            "description": {
                "common": "goserelin increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eribulin",
            "description": {
                "common": "goserelin increases toxicity of eribulin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "goserelin increases toxicity of erythromycin base by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "goserelin increases toxicity of erythromycin ethylsuccinate by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "goserelin increases levels of erythromycin lactobionate by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "goserelin increases toxicity of erythromycin stearate by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ezogabine",
            "description": {
                "common": "goserelin increases levels of ezogabine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "goserelin increases toxicity of fingolimod by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flecainide",
            "description": {
                "common": "goserelin increases toxicity of flecainide by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluconazole",
            "description": {
                "common": "goserelin increases toxicity of fluconazole by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "formoterol",
            "description": {
                "common": "goserelin increases toxicity of formoterol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "goserelin and fostemsavir both increase  QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gallium Ga 68 PSMA-11",
            "description": {
                "common": "goserelin will decrease the level or effect of gallium Ga 68 PSMA-11 by  unspecified interaction mechanism. Modify Therapy/Monitor Closely. Androgen deprivation therapy and other therapies targeting the androgen pathway may result in changes in the uptake of gallium Ga 68 PSMA-11 in prostate cancer. The effect of ADT on the performance of gallium Ga 68 PSMA-11 is unknown."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemifloxacin",
            "description": {
                "common": "goserelin increases toxicity of gemifloxacin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemtuzumab",
            "description": {
                "common": "goserelin and gemtuzumab both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gilteritinib",
            "description": {
                "common": "gilteritinib and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "granisetron",
            "description": {
                "common": "granisetron and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "goserelin increases toxicity of haloperidol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyzine",
            "description": {
                "common": "hydroxyzine and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indacaterol, inhaled",
            "description": {
                "common": "goserelin increases toxicity of indacaterol, inhaled by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lapatinib",
            "description": {
                "common": "goserelin increases levels of lapatinib by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenvatinib",
            "description": {
                "common": "goserelin and lenvatinib both increase  QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levofloxacin",
            "description": {
                "common": "goserelin increases toxicity of levofloxacin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "goserelin decreases effects of metformin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methadone",
            "description": {
                "common": "goserelin increases toxicity of methadone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "mirtazapine and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxifloxacin",
            "description": {
                "common": "goserelin increases toxicity of moxifloxacin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "goserelin increases toxicity of ofloxacin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ondansetron",
            "description": {
                "common": "goserelin increases toxicity of ondansetron by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "osilodrostat",
            "description": {
                "common": "osilodrostat and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "osimertinib",
            "description": {
                "common": "goserelin increases toxicity of osimertinib by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin will increase the level or effect of goserelin by  Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pasireotide",
            "description": {
                "common": "goserelin increases toxicity of pasireotide by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pazopanib",
            "description": {
                "common": "goserelin increases toxicity of pazopanib by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentamidine",
            "description": {
                "common": "goserelin increases toxicity of pentamidine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perflutren",
            "description": {
                "common": "goserelin increases toxicity of perflutren by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primaquine",
            "description": {
                "common": "primaquine and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propafenone",
            "description": {
                "common": "goserelin increases toxicity of propafenone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ranolazine",
            "description": {
                "common": "goserelin increases toxicity of ranolazine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "romidepsin",
            "description": {
                "common": "goserelin increases toxicity of romidepsin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "goserelin increases toxicity of saquinavir by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and goserelin both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solifenacin",
            "description": {
                "common": "solifenacin and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sorafenib",
            "description": {
                "common": "goserelin increases toxicity of sorafenib by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sunitinib",
            "description": {
                "common": "goserelin increases toxicity of sunitinib by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "tacrolimus and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telavancin",
            "description": {
                "common": "goserelin increases toxicity of telavancin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "goserelin increases toxicity of trazodone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valbenazine",
            "description": {
                "common": "valbenazine and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "goserelin increases toxicity of voriconazole by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vorinostat",
            "description": {
                "common": "vorinostat and goserelin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maitake",
            "description": {
                "common": "maitake increases effects of goserelin by pharmacodynamic synergism. Minor/Significance Unknown. Maitake mushroom has anti-tumor effects (animal/in vitro research)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "taurine",
            "description": {
                "common": "goserelin decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Hot flashes",
            "percent": "62"
        },
        {
            "name": "Sexual dysfunction",
            "percent": "21"
        },
        {
            "name": "Decreased erections",
            "percent": "18"
        },
        {
            "name": "Lower urinary tract symptoms",
            "percent": "13"
        },
        {
            "name": "Hot flushes",
            "percent": "96"
        },
        {
            "name": "Vaginitis",
            "percent": "75"
        },
        {
            "name": "Headache",
            "percent": "75"
        },
        {
            "name": "Libido decreased",
            "percent": "61"
        },
        {
            "name": "Emotional lability",
            "percent": "60"
        },
        {
            "name": "Depression",
            "percent": "54"
        },
        {
            "name": "Sweating",
            "percent": "45"
        },
        {
            "name": "Acne",
            "percent": "42"
        },
        {
            "name": "Breast atrophy",
            "percent": "33"
        },
        {
            "name": "Seborrhea",
            "percent": "26"
        },
        {
            "name": "Peripheral edema",
            "percent": "21"
        },
        {
            "name": "Breast enlargement",
            "percent": "18"
        },
        {
            "name": "Pelvic symptoms",
            "percent": "18"
        },
        {
            "name": "Pain",
            "percent": "17"
        },
        {
            "name": "Dyspareunia",
            "percent": "14"
        },
        {
            "name": "Infection",
            "percent": "13"
        },
        {
            "name": "Libido increased",
            "percent": "12"
        },
        {
            "name": "Asthenia",
            "percent": "11"
        },
        {
            "name": "Insomnia",
            "percent": "11"
        },
        {
            "name": "Vasodilation",
            "percent": "57"
        },
        {
            "name": "Headache",
            "percent": "32"
        },
        {
            "name": "Sweating",
            "percent": "16"
        },
        {
            "name": "Abdominal pain",
            "percent": "11"
        },
        {
            "name": "Hot flashes",
            "percent": "70"
        },
        {
            "name": "Tumor flare",
            "percent": "23"
        },
        {
            "name": "Nausea",
            "percent": "11"
        },
        {
            "name": "Lethargy",
            "percent": "8"
        },
        {
            "name": "Pain",
            "percent": "30"
        },
        {
            "name": "worsened first",
            "percent": "8"
        },
        {
            "name": "days",
            "percent": "7"
        },
        {
            "name": "Edema",
            "percent": "7"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "6"
        },
        {
            "name": "Rash",
            "percent": "6"
        },
        {
            "name": "Sweating",
            "percent": "5"
        },
        {
            "name": "Anorexia",
            "percent": "5"
        },
        {
            "name": "COPD",
            "percent": "5"
        },
        {
            "name": "CHF",
            "percent": "5"
        },
        {
            "name": "Dizziness",
            "percent": "5"
        },
        {
            "name": "Insomnia",
            "percent": "5"
        },
        {
            "name": "Nausea",
            "percent": "8"
        },
        {
            "name": "Nausea",
            "percent": "7"
        },
        {
            "name": "Hirsutism",
            "percent": "7"
        },
        {
            "name": "Breast pain",
            "percent": "7"
        },
        {
            "name": "Abdominal pain",
            "percent": "7"
        },
        {
            "name": "Back pain",
            "percent": "6"
        },
        {
            "name": "Dizziness",
            "percent": "6"
        },
        {
            "name": "Application site reactions",
            "percent": "5"
        },
        {
            "name": "Flu syndrome",
            "percent": "5"
        },
        {
            "name": "Pharyngitis",
            "percent": "4"
        },
        {
            "name": "Hair disorders",
            "percent": "3"
        },
        {
            "name": "Voice alterations",
            "percent": "3"
        },
        {
            "name": "Myalgia",
            "percent": "3"
        },
        {
            "name": "Nervousness",
            "percent": "3"
        },
        {
            "name": "Weight gain",
            "percent": "2"
        },
        {
            "name": "Leg cramps",
            "percent": "2"
        },
        {
            "name": "Increased appetite",
            "percent": "2"
        },
        {
            "name": "Pruritus",
            "percent": "1"
        },
        {
            "name": "Hypertonia",
            "percent": "9"
        },
        {
            "name": "Pelvic pain",
            "percent": "7"
        },
        {
            "name": "Migraine",
            "percent": "7"
        },
        {
            "name": "Dysmenorrhea",
            "percent": "6"
        },
        {
            "name": "Hypertension",
            "percent": "6"
        },
        {
            "name": "Uterine hemorrhage",
            "percent": "5"
        },
        {
            "name": "Nausea",
            "percent": "5"
        },
        {
            "name": "Nervousness",
            "percent": "5"
        },
        {
            "name": "Vulvovaginitis",
            "percent": "4"
        },
        {
            "name": "Back pain",
            "percent": "4"
        },
        {
            "name": "Menorrhagia",
            "percent": "3"
        },
        {
            "name": "Depression",
            "percent": "3"
        },
        {
            "name": "Sinusitis",
            "percent": "1"
        },
        {
            "name": "Vaginitis",
            "percent": "5"
        },
        {
            "name": "Edema",
            "percent": "5"
        },
        {
            "name": "Malaise",
            "percent": "4"
        },
        {
            "name": "fatigue",
            "percent": null
        },
        {
            "name": "lethargy",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        }
    ]
}